status (5). Breast MRI is considered optional, with attention given to cases with mammographically occult tumors. Consideration of additional imaging studies, such as bone scintigraphy and CT, is directed by signs or symptoms (2, 5) .
Anatomic tNM Staging
Anatomic TNM staging may be subdivided into four categories: (a) clinical staging, which is based on the findings from clinical examination, diagnostic imaging, and/or core biopsy specimens; (b) pathologic staging, which is based on surgical specimens (including sentinel lymph node biopsy specimens); (c) posttherapy staging, which is performed after neoadjuvant chemotherapy, radiation therapy, or hormonal therapy, and may include both clinical and pathologic information; and (d) restaging in the event of tumor recurrence (2) . Because the purpose of this article is to focus on important concepts for the radiologist, anatomic clinical staging will primarily be discussed. Imaging studies are considered to be components of staging if they are performed within 4 months of diagnosis or through the completion of surgery, whichever time period is longer if the disease has not progressed.
Clinical anatomic staging assesses the extent of disease involving the primary tumor (Tis to T4), regional lymph node status (N0 to N3), and distant metastasis (M0 or M1) to yield an overall anatomic stage (0 to IV). The final anatomic stage then carries a prognosis from most favorable (stage 0) to least favorable (stage IV). The 5-year survival rate for patients with disease localized to the breast is 98.9%, whereas the 5-year survival rate for patients with distant metastatic disease is 26.9% (6).
Clinical Anatomic Staging of the Primary tumor
The categories of clinical anatomic staging of the primary tumor (T categories) range from Tis to T4 and are identical to those of pathologic anatomic staging of the primary tumor (Table 1 ) (3). DCIS and Paget disease without underlying invasive carcinoma or DCIS are both considered to be category Tis, regardless of the size of the tumor (Fig 1) . One of the changes for breast cancer staging in the eighth edition of the AJCC manual is that lobular carcinoma in situ is no longer included as a Tis category but rather is considered a benign entity that confers a higher risk of future breast cancer. Pleomorphic lobular carcinoma in situ is also not distinguished separately, because insufficient data exist with regard to outcomes for this variant of lobular carcinoma in situ. T1 disease is subcategorized as T1mi (tumor size ≤ 1 mm), T1a (tumor size > 1 mm but ≤ 5 mm),T1b (tumor size > 5 mm but ≤ 10 mm), or eighth edition includes two staging systems-the anatomic stage, which includes the size of the primary tumor, nodal status, and distant metastasis; and the prognostic stage, which includes tumor grade, hormone receptor and oncogene expression, and the results of multigene panel testingto accurately predict a patient's outcome (2, 3) . Prognostic staging is preferred for patient care, but anatomic staging may be used in regions of the world where biomarker testing is not available (4). The integration of prognostic staging is of particular importance for breast cancer, because recent advances in therapies that are based on an individual's hormone receptor status and the findings from multigene panels have revolutionized strategies for treatment.
In this article, anatomic TNM staging and the major changes in the eighth edition of the AJCC system for breast cancer staging are reviewed; the radiologist is familiarized with prognostic biomarkers and prognostic staging; and key sites of disease that may alter clinical management are identified. The AJCC staging system for breast cancer applies to invasive carcinomas and ductal carcinoma in situ (DCIS), with or without microinvasion, and does not apply to breast sarcomas, phyllodes tumors, or breast lymphomas. To determine a patient's breast cancer stage, the National Comprehensive Cancer Network recommends the following workup: history and physical examination; blood tests; diagnostic bilateral mammography and US, as necessary; pathologic assessment review; and determination of hormone receptor tEAChiNg POiNtS ■ The eighth edition includes two staging systems-the anatomic stage, which includes the size of the primary tumor, nodal status, and distant metastasis; and the prognostic stage, which includes tumor grade, hormone receptor and oncogene expression, and the results of multigene panel testing-to accurately predict a patient's outcome.
■ One of the changes for breast cancer staging in the eighth edition of the AJCC manual is that lobular carcinoma in situ is no longer included as a Tis category but rather is considered a benign entity that confers a higher risk of future breast cancer.
■ Axillary lymph node levels are defined by the relationship of the lymph node to the pectoralis minor muscle.
■ For patients with T1 and T2 hormone receptor-positive, HER2-negative, and lymph node-negative tumors, an Oncotype DX recurrence score of less than 11 places the tumor into the same prognostic category as T1aN0M0 or T1bN0M0 tumors, and the tumor is staged with the AJCC prognostic stage group table as prognostic stage I.
■ Generally, if the primary tumor occupies the equivalent of one quadrant of the breast or less, breast conservation surgery can be attempted, including in patients with multifocal disease. On the other hand, for cases of multicentric disease (disease occupying the equivalent of more than one quadrant of the breast), mastectomy is often required.
pectoral muscles by tumor (without involvement of the ribs, intercostal muscles, serratus anterior muscle, or skin) is not considered chest wall invasion and does not affect T staging. Involvement of the pectoral muscles and/or chest wall is best assessed with contrast material-enhanced MRI. At imaging, tumor size in at least the longest dimension should be precisely measured to the nearest millimeter. If the same tumor's measurements differ at mammography, US, and/or MRI, then MRI measurements are usually used. If the tumor size differences are so large as to affect T staging, then imaging-guided biopsy could be considered to better define the extent of disease. Tumor sizes are rounded up or down to the nearest millimeter, with the exception of tumor sizes between 1.0 mm and 1.4 mm, which are rounded up to 2 mm. In this scenario, rounding down would result in the tumor being categorized as microinvasive carcinoma (T1mi), which is defined as a tumor size of 1.0 mm or less. In addition to tumor size, extension of the tumor to the nipple, skin, pectoral muscles, and chest wall should also be reported.
T1c (tumor size > 10 mm but ≤ 20 mm) (Fig 2) . With T2 disease, the size of the primary tumor is more than 20 mm but less than or equal to 50 mm (Fig 3) . With T3 disease, the size of the primary tumor is more than 50 mm. T4 disease is subcategorized as T4a (chest wall invasion), T4b (macroscopic skin changes including ulceration and/or satellite skin nodules and/or edema), T4c (combined features of T4a and T4b), and T4d (inflammatory carcinoma) (Fig 4) .
Note that the chest wall includes the ribs, intercostal muscles, and serratus anterior muscle, but not the pectoral muscles. Thus, involvement of the 
Axillary Lymph Node Levels and Clinical Anatomic Nodal Staging
Axillary lymph node levels are defined by the relationship of the lymph node to the pectoralis minor muscle (Figs 5, 6). Level I axillary nodes are located lateral to the lateral border of the pectoralis minor muscle. Level II axillary nodes are located between the medial and lateral borders of the pectoralis minor muscle and also include the interpectoral (Rotter's) lymph nodes. Level III axillary nodes are located medial to the medial margin of the pectoralis minor muscle and inferior to the clavicle. For clinical anatomic nodal staging, the cN categories range from cNX to cN3 (Table 2 ) (3). Note that pathologic anatomic nodal staging differs from clinical anatomic nodal staging, often by incorporating the number of the various nodes involved. Category cN0 disease reflects absent regional lymph node metastases. Category cN1 disease is subcategorized as cN1 (metastases to movable ipsilateral level I and/ or level II axillary nodes) or cN1mi (micrometastases) (Fig 7) . Category cN2 disease may be subcategorized into cN2a (metastases to fixed or matted ipsilateral level I and/or level II axillary nodes) or cN2b (metastases to ipsilateral internal mammary nodes without axillary metastases). Category cN3 disease may be subcategorized as cN3a (metastases to ipsilateral level III axillary nodes), cN3b (metastases to ipsilateral internal mammary nodes with level I and/or level II axillary metastases), or cN3c (metastases to ipsilateral supraclavicular nodes) (Fig 8) . Note that intramammary lymph nodes (lymph nodes within the breast) are considered axillary lymph nodes for the purposes of nodal staging. Metastases to other lymph nodes not listed previously in Metastases to ipsilateral internal mammary nodes with level I and/or level II axillary metastases cN3c
Metastases to ipsilateral supraclavicular nodes this paragraph, including cervical lymph nodes, contralateral internal mammary lymph nodes, or contralateral axillary lymph nodes, are considered distant metastases. Imaging is not considered necessary to determine the cN stage, and routine use of axillary US is controversial. Historically, if a diagnosis was made of a biopsy-proven metastatic axillary lymph node before surgery, the patient would undergo axillary lymph node dissection; however, in the results of the American College of Surgeons Oncology Group Z0011 randomized trial, investigators demonstrated that axillary lymph node dissection may not be necessary in clinically node-negative women with one or two positive sentinel lymph nodes who are being treated with breast-conserving therapy and adjuvant systemic therapy (7) . Given that the surgical management of the axilla is changing, the routine use of axillary US requires further investigation. However, if a patient has imaging evidence or histopathologic confirmation of axillary level I or level II lymph node metastases, then imaging studies to evaluate the axillary level III lymph nodes, internal mammary lymph nodes, and supraclavicular lymph nodes are warranted. These lymph nodes may be imaged with US or may be depicted with breast MRI or chest CT.
Clinical Staging of Metastases
Clinical staging of metastases ranges from M0 to M1 (Table 3 ) (3). M0 disease reflects an absence of distant metastases, and M1 disease reflects the presence of distant metastases ( Fig  9) . As mentioned in the previous section on nodal staging, metastases to the cervical lymph nodes, contralateral internal mammary lymph nodes, or contralateral axillary lymph nodes are considered to be distant metastases. The four most common sites of metastatic disease are bone, lung, brain, and liver.
To be considered clinically free of metastases (category cM0), imaging studies of distant sites are not considered necessary. Routine imaging studies are not thought to be necessary in patients without symptoms who have clinical 
Anatomic Staging Summary
Primary tumor size, combined with the existence of regional lymphadenopathy and distant metastases, results in an overall anatomic stage that ranges from stage 0 to stage IV (Table 4 ) (3).
Prognostic Markers and Prognostic Staging
The addition of the tumor grade, hormone receptor and oncogene expression (including ER, PR, and HER2), and multigene panel results to anatomic information offers more accurate prognostication. Although lower-grade tumors, ER-positive tumors, and PR-positive tumors tend to be more favorable across populations, the results from multigene panels offer even further individualized prognostic information (4).
tumor grade
According to the eighth edition of the AJCC manual (3), the tumor grade defined by the histologic grading system of Scarff, Bloom, and Richardson 
ER, PR, and hER2 Expression
According to the eighth edition of the AJCC manual, all invasive carcinomas should have the ER, PR, and HER2 status determined by using appropriate assays whenever possible. It is known that tamoxifen therapy and other endocrine therapies can slow the progression of ER-positive and PR-positive tumors (10, 11) . The amplification or overexpression of ERBB2 (formerly HER2), which is an oncogene, is associated with a worse prognosis regardless of nodal status (12, 13) . HER2 expression is more commonly present in invasive ductal carcinoma, rather than invasive lobular carcinoma, but is associated with a poor prognosis when found in lobular carcinoma (14) . Anti-HER2 therapies, including the monoclonal antibody trastuzumab, have been shown to be effective in improving the prognosis of patients with HER2-positive disease (15) .
gene Expression Profiling
In addition to individual tumor markers, advances in breast cancer genomics have led to prognostic profiling that is based on patterns of expression of combinations of up to thousands of genes in tumor cells. Main genomic subtypes of breast cancer include luminal A, luminal B, luminal HER2, HER2-enriched, basal-like, and triple-negative (ER-negative, PR-negative, HER2-negative) nonbasal tumors, with each subtype having different prognostic implications (16) . Specifically, patients with luminal A tumors (which may be hormone receptor positive or negative) have the best prognosis, with an 8% rate of local relapse at 10 years after either breast conservation surgery or mastectomy and a 3%-4% rate of regional relapse after either breast conservation surgery or mastectomy (16) . Gene profiling is not limited to primary tumor specimens, as profiling of circulating tumor cells has also been studied (17) . Circulating tumor cell count is currently used as a prognosticating tool in patients with metastatic breast cancer, with a level of circulating tumor cells equal to or more than 5/7.5-30 mL of blood associated with a shorter period of disease-free survival (18, 19) . In the results of preliminary studies, investigators have found that evaluation of messenger RNA from these circulating tumor cells has shown promise of providing an even more accurate predictor of the response to treatment in patients with metastatic breast cancer (17) .
Multigene Panels
Gene expression profiling has led to the development of several multigene panels, many of which have been validated as prognostic tools. The Oncotype DX Breast Recurrence Score (Genomic Health, Redwood City, Calif) test is the most validated multigene panel and is currently incorporated into prognostic staging of the eighth edition of the AJCC manual (20) . Oncotype DX recurrence scores are currently used for hormone-positive node-negative tumors to evaluate the additive benefit of adjuvant chemotherapy in addition to hormonal therapy. The multigene panel is used to evaluate 16 genes and five reference genes, in order to predict the likelihood of recurrence in patients undergoing endocrine therapy alone, with categorization of an individual patient as having low, intermediate, or high risk of recurrence (21, 22) . For patients with a low-risk recurrence score (generally <18), the model predicts no additional benefit of chemotherapy (21, 22) .
The eighth edition of the AJCC manual now incorporates Oncotype DX recurrence scores to potentially downstage tumors (4). For patients with T1 and T2 hormone receptor-positive, HER2-negative, and lymph node-negative tumors, an Oncotype DX recurrence score of less than 11 places the tumor into the same prognostic category as T1aN0M0 or T1bN0M0 tumors, and the tumor is staged with the AJCC prognostic stage group table as prognostic stage I (Fig 10) 
Stage Migration
The incorporation of biomarkers into the prognostic staging system results in stage migration for certain patients. For example, a patient with a T2N1M0 cancer that is grade 2-3 and triple negative would be categorized as stage IIB according to AJCC anatomic staging and as stage IIIB according to AJCC clinical prognostic staging. A patient with a T3N0M0 cancer that is grade 1-3 and expresses ER, PR, and HER2 would be categorized as stage IIB according to AJCC anatomic staging and as stage IB according to AJCC clinical prognostic staging. In general, triple-negative tumors are "upstaged" in their prognostic stage, and HER2 expression is a "downstaging" factor (due to the success of anti-HER2 therapies) (24) . Note that for the prognostic staging system, it is assumed that patients receive appropriate systemic treatment, including anti-HER2 therapy, chemotherapy, and hormonal therapy (25) . Examples of differences between anatomic and prognostic stage groups are shown in Table 5 (3). In the eighth edition of the AJCC manual, the complete table incorpo- rating TNM staging with tumor grade, hormone receptor expression, and oncogene expression is several pages in length.
validation of the AJCC Prognostic Staging System, Eighth Edition
Using both single institution and population databases, several recent groups of investigators have validated the superior accuracy of prognostic staging, compared with anatomic staging (25) (26) (27) (28) (29) (30) (31) (32) (33) .
In the results of an initial study of 3327 patients treated with surgery from 2007 to 2013 at the MD Anderson Cancer Center, investigators demonstrated that disease-specific survival was more precise with staging systems incorporating tumor grade, ER status, and HER2 status, compared with anatomic information alone (27) . In the findings from a subsequent study of 54 727 patients treated from 2005 to 2009 who were identified in the California Cancer Registry, the prognostic stage provided more accurate prognostic information than the anatomic stage alone (33) .
Additional Changes in the AJCC Manual, Eighth Edition
Additional changes apart from prognostic staging in the eighth edition of the AJCC manual are largely related to pathologic staging. Major changes that are of interest to radiologists are described in Table 6 (3). 
Sites of Disease that May Affect Clinical Management
The main consideration in determining whether breast conservation surgery is a viable option is the size of the primary tumor. Generally, if the primary tumor occupies the equivalent of one quadrant of the breast or less, breast conservation surgery can be attempted, including in patients with multifocal disease. On the other hand, for cases of multicentric disease (disease occupying the equivalent of more than one quadrant of the breast), mastectomy is often required (Figs 11, 12) . Regional adenopathy may also affect surgical management; that is, if a large axillary tumor burden is identified before surgery, a full axillary node dissection may be performed rather than sentinel lymph node biopsy, and radiation therapy to the axilla may be considered. Similarly, internal mammary, supraclavicular, and infraclavicular adenopathy may affect the radiation field.
Patients with T4 disease (chest wall invasion, skin invasion, or inflammatory breast cancer) undergo neoadjuvant chemotherapy, followed by surgical management once a treatment response is achieved (either mastectomy or lumpectomy, both with sentinel node biopsy) and adjuvant radiation therapy with or without adjuvant hormonal therapy or immunotherapy, depending on tumor type; thus, T4 disease is critical to identify in these patients who require preoperative chemotherapy (Fig 13) . Findings that result in stage III disease usually warrant additional imaging workup, including chest CT, abdominal and/ or pelvic CT or MRI, bone scintigraphy or PET/ CT with radioactive sodium fluoride, or PET/CT with fluorine 18 fluorodeoxyglucose (Fig 14) .
Conclusion
The eighth edition of the AJCC Cancer Staging Manual (3) combines prognostic biomarkers with the traditional anatomic TNM staging system to best estimate individual outcomes. An Oncotype DX recurrence score of less than 11 in patients with T1 and T2 hormone recep- Tumor sizes will not be additive for clinical (cT) or pathologic (pT) tumor classification; rather, the size of the largest tumor will be used.
Definition of T4b
Satellite skin lesions must be separate from the primary tumor and macroscopic to qualify as T4b.
Definition of cNX
The cNX category is not to be used unless all lymph nodes have been removed and cannot be evaluated with physical examination or imaging studies. The cN0 category is to be used when (a) any evaluation of the lymph nodes is possible and (b) the findings from physical examination or an imaging study or studies are negative.
Removal of pM0
All cases are to be considered either cM0 or cM1; however, if cM1 is confirmed with histopathologic results, then pM1 should be used. Definition of complete pathologic response (pCR)
Residual invasive tumor in the blood vessels, lymph vessels, or lymph nodes precludes classification as pCR.
Source.-Reference 3. tor-positive, HER2-negative, lymph node-negative tumors will result in a prognostic stage I. Key sites of disease for the radiologist to identify include multifocal disease compared with multicentric disease, axillary lymphadenopathy (level I, II, or III), internal mammary and supraclavicular adenopathy, chest wall invasion, skin involvement, inflammatory breast cancer, and distant metastases. 
